{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-019536","form_type":"8-K","ticker":"BIOA","cik":"0001709941","company_name":"BioAge Labs, Inc.","filed_at":"2026-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.965901+00:00","generated_at":"2026-05-16T08:49:04.384833+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioAge Labs prices upsized $115M public offering of 5.9M shares at $19.50/share","bullets":["5,897,435 shares offered at $19.50/share; gross proceeds ~$115M, net ~$107.6M.","Underwriters have 30-day option to purchase up to 884,615 additional shares.","Proceeds to fund BGE-102, NLRP3, and APJ programs, plus working capital and debt reduction.","Goldman Sachs, Piper Sandler, and Citigroup are joint book-running managers.","Offering expected to close on January 23, 2026, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-019536","json":"https://secwatch.observer/filing/0001193125-26-019536.json","markdown":"https://secwatch.observer/filing/0001193125-26-019536.md","text":"https://secwatch.observer/filing/0001193125-26-019536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526019536/0001193125-26-019536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526019536/bioa-20260121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:49:04.384833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f89fb019d1114e39b57e53add1847fae1e9adda","claim":"BioAge Labs, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters valued at $107.6 million (effective 2026-01-21).","evidence_excerpt":"On January 21, 2026, BioAge Labs, Inc., a Delaware corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters named therein (the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a price of $19.50 per Underwritten Share (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526019536/0001193125-26-019536-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters"},{"label":"Value","value":"$107.6 million"},{"label":"Effective","value":"2026-01-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}